8-O-乙酰山栀苷甲酯

8-O-Acetylshanzhiside methyl ester

	产品编号	CFN98966
	CAS编号	57420-46-9
	分子式 = 分子量	C₁₉H₂₈O₁₂ = 448.4
	产品纯度	>=98%
	物理属性	Powder
	化合物类型	Iridoids
	植物来源	The herbs of Lamiophlomis rotata (Benth.) Kudo.
ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用

提供自定义包装

产品名称	产品编号	CAS编号	包装	QQ客服
8-O-乙酰山栀苷甲酯	CFN98966	57420-46-9	10mg	QQ客服：2056216494
8-O-乙酰山栀苷甲酯	CFN98966	57420-46-9	20mg	QQ客服：2056216494
8-O-乙酰山栀苷甲酯	CFN98966	57420-46-9	50mg	QQ客服：2056216494
8-O-乙酰山栀苷甲酯	CFN98966	57420-46-9	100mg	QQ客服：2056216494

存储与注意事项

1. 在您收到产品后请检查产品。如无问题，请将产品存入冰霜并且样品瓶保持密封，产品可以存放长达24个月（2-8摄氏度）。

2. 只要有可能，产品溶解后，您应该在同一天应用于您的实验。但是，如果您需要提前做预实验，或者需要全部溶解，我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。通常，这些可用于长达两周。使用前，打开样品瓶前，我们建议您将产品平衡至室温至少1小时。

3. 需要更多关于溶解度，使用和处理的建议？请发送电子邮件至：service@chemfaces.com

订购流程

1. 在线订购

请联系我们QQ客服

2. 电话订购

请拨打电话：
027-84237683 或 027-84237783

3. 邮件或传真订购

发送电子邮件到: manager@chemfaces.com 或
发送传真到：027-84254680

提供订购信息

为了方便客户的订购，请需要订购ChemFaces产品的客户，在下单的时候请提供下列信息，以供我们快速为您建立发货信息。

1. 产品编号（CAS No.或产品名称）

2. 发货地址

3. 联系方法 (联系人，电话）

4. 开票抬头 (如果需要发票的客户）

5. 发票地址（发货地址与发票地址不同）

发货时间

1. 付款方式为100%预付款客户，我们将在确认收到货款后当天或1-3个工作日发货。

2. 付款方式为月结的客户，我们承诺在收到订单后当天或1-3个工作日内发货。

3. 如果客户所需要的产品，需要重新生产，我们有权告知客户，交货时间需要延期。

Description:

8-O-Acetylshanzhiside methyl ester(ND01) has potential against cerebral ischemic injury and experimental myocardial ischemia injury, it can increase angiogenesis and improve functional recovery after stroke. ND01 protects diabetic brain against I/R injury by alleviating diabetic cerebral I/R injury and attenuating blood–brain barrier (BBB) breakdown, and its protective effects may involve HMGB-1 and NF-κB signalling pathway.

Targets:

In vitro:

Eur J Pharm Sci. 2012 Aug 30;47(1):124-30.

Cardioprotection with 8-O-acetylshanzhiside methylester on experimental myocardial ischemia injury.[Pubmed: 22677812 ]

8-O-acetylshanzhiside methyl ester (ND01) was isolated from the leaves of Lamiophlomis rotata (Benth.) Kudo. In this study, we investigated the anti-myocardial ischemia and reperfusion (I/R) injury effects of ND01 in vivo and elucidated the potential mechanism in vitro.
METHODS AND RESULTS:
The results indicated that ND01 significantly attenuated hypoxia-induced cytotoxicity in a concentration-dependent manner in H9c2 cells. Treatment of H9c2 cells with ND01 9 μM blocked TNF-α-induced nuclear factor kappaB (NF-κB) phosphorylation by blocking High-mobility group box1 (HMGB1) expression. Treatment of rats with ND01 10mg/kg, (i.v.) protected the animals from myocardial I/R injury as indicated by a decrease in infarct volume, improvement in hemodynamics and reduction of myocardial damage severity. Treatment with ND01 also lowered serum levels of pro-inflammatory factors and reduced High mobility group box-1 protein (HMGB1) and phosphorylated NF-κB expression in ischemic myocardial tissue. Additionally, continuous i.v. of ND01 14 days attenuated cardiac remodeling.
CONCLUSIONS:
These protective effects suggested that ND01 might be due to block of myocardial inflammatory cascades through an HMGB1-dependent NF-κB signaling pathway.

In vivo:

Basic Clin Pharmacol Toxicol. 2011 Jan;108(1):21-7.

Effect of 8-O-acetyl shanzhiside methylester increases angiogenesis and improves functional recovery after stroke.[Pubmed: 20735376]

We investigated whether 8-O-acetylshanzhiside methyl ester (ND01) regulates angiogenesis and thereby improves functional outcome after stroke.
METHODS AND RESULTS:
Adult male rats were subjected to 1 hr of middle cerebral artery occlusion (MCAO) and reperfusion, and treated with or without different doses (5 and 10 mg/kg) of ND01, starting 24 hr after ischaemia and reperfusion (I/R) and by intravenous injection daily for 14 days. Neurological functional tests were performed and cerebral Evans blue extravasation was measured. Angiogenesis and angiogenic factor expression were measured by immunohistochemistry and Western blot, respectively.
CONCLUSIONS:
The results indicated that ND01 significantly promoted angiogenesis in the ischaemic brain and improved functional outcome after stroke. ND01 also significantly increased vascularization compared with vehicle treatment. ND01 increased the expression of VEGF, Ang1, phosphorylation of Tie2 and Akt VEGF. The Ang1/Tie2 axis and Akt pathways appear to mediate ND01-induced angiogenesis.

J Ethnopharmacol . 2016 Jul 1;187:232-8.

A new anti-fibrinolytic hemostatic compound 8-O-acetyl shanzhiside methylester extracted from Lamiophlomis rotata[Pubmed: 27085939]

Abstract Background: Fibrinolysis prevents blood clots from growing and becoming problematic. Antifibrinolytics are used as inhibitors of fibrinolysis. Aprotinin was doubted after identification of major side effects, especially on kidney. Lysine analogues has their own defects and whether they are adequate substitutes for aprotinin is still under doubt. Lamiophlomis rotata (Benth.) Kudo. was previous found to have hemostatic activity. But the active compound in L. rotata and its hemostatic mechanism were unknown. Objectives: To find the major hemostatic compound in L. rotata and identify its haemostasis mechanism. Methods: Traumatic hemorrhage model and coagulant activity assays were monitored in mice and platelets in drug treatment group and control group. Hyperfibrinolysis model was established by intravenous administration of urokinase in mice. Capillary blood clotting time (CBCT), activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), fibrinogen and euglobulin clot lysis time (ECLT) were measured. Results: The anti-fibrinolytic activity come from 8-O-Acetyl shanzhiside methylester (ASM) one of the highest iridoid glycosides contents in TIG extracted from L. rotata. ASM significantly (P<0.05) shorten CBCT and reduced blood loss volume in vivo, but did not influence mice APTT, PT or TT. In particular, it significantly prolonged ECLT in hyperfibrinolysis mice. It indicated that ASM could inhibit fibrinolysis. ASM was also effective in CBCT, traumatic bleeding volume and ECLT in hyperfibrinolysis mice model. Conclusions: ASM was the major hemostatic compound in L. rotata. The haemostasis mechanism of ASM was achieved by anti-fibrinolytic activity. ASM was a new fibrinolysis inhibitor as iridoid glycoside compound. Keywords: Antifibrinolytics; Bleeding volume; Hemostatics; Hyperfibrinolysis; Iridoid glycosides.

产品名称	产品编号	CAS编号	分子式 = 分子量	位单	联系QQ
山栀苷甲酯; Shanzhiside methylester	CFN97107	64421-28-9	C₁₇H₂₆O₁₁ = 406.4	20mg	QQ客服：215959384
8-O-乙酰山栀苷甲酯; 8-O-Acetylshanzhiside methyl ester	CFN98966	57420-46-9	C₁₉H₂₈O₁₂ = 448.4	20mg	QQ客服：2159513211
(E)-6-O-对香豆酰鸡屎藤次苷甲酯; (E)-6-O-(p-coumaroyl)scandoside methyl ester	CFN95192	83946-90-1	C₂₆H₃₀O₁₃ = 550.5	10mg	QQ客服：215959384
6-O-反式对香豆酰山栀苷甲酯; 6-O-trans-p-Coumaroylshanzhiside methyl ester	CFN99359	1246012-26-9	C₂₆H₃₂O₁₃ = 552.5	5mg	QQ客服：2056216494
6Beta-野芝麻新甙; 6beta-Hydroxyipolamiide	CFN97445	87797-84-0	C₁₇H₂₆O₁₂ = 422.4	5mg	QQ客服：1457312923
环烯醚萜B; Phlorigidoside B	CFN98356	288248-46-4	C₁₉H₂₈O₁₃ = 464.4	5mg	QQ客服：2056216494
6-O-苯甲酰环烯醚萜B; 6-O-Benzoylphlorigidoside B	CFN99357	1246012-24-7	C₂₆H₃₂O₁₄ = 568.5	5mg	QQ客服：1457312923
6-O-trans-Cinnamoylphlorigidoside B; 6-O-trans-Cinnamoylphlorigidoside B	CFN99358	1246012-25-8	C₂₈H₃₄O₁₄ = 594.6	5mg	QQ客服：215959384

	1 mg	5 mg	10 mg	20 mg	25 mg
1 mM	2.2302 mL	11.1508 mL	22.3015 mL	44.603 mL	55.7538 mL
5 mM	0.446 mL	2.2302 mL	4.4603 mL	8.9206 mL	11.1508 mL
10 mM	0.223 mL	1.1151 mL	2.2302 mL	4.4603 mL	5.5754 mL
50 mM	0.0446 mL	0.223 mL	0.446 mL	0.8921 mL	1.1151 mL
100 mM	0.0223 mL	0.1115 mL	0.223 mL	0.446 mL	0.5575 mL

8-O-乙酰山栀苷甲酯

8-O-Acetylshanzhiside methyl ester

信息支持

联系方式